Patients Clinical Trial

Recent News

07/21/2014
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Second Quarter 2014
Read More

07/01/2014
GI Dynamics Announces Departure of Chief Commercial Officer
Read More

06/16/2014
Data Presented at ADA Show the Effects of GI Dynamics’ EndoBarrier® Therapy on Glycemic Control and Reducing Diabetes Medication in Patients with Type 2 Diabetes and Obesity
Read More


EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE